Hereditary Angioedema Consensus 2010 by Bowen, Tom
EDITORIAL Open Access
Hereditary Angioedema Consensus 2010
Tom Bowen
Editorial
The 2010 International Consensus Algorithm for the
Diagnosis, Therapy and Management of Hereditary
Angioedema was arrived at during the Canadian Heredi-
tary Angioedema Network (CHAEN)/Réseau Canadien
d’angioédème héréditaire (R C A H )s e c o n dm e e t i n gh e l d
May 15
th/16
th, 2010, Toronto, Canada and was cospon-
sored by CHAEN/RCAH, the Canadian Society of
Allergy and Clinical Immunology, and the University of
Calgary and was funded through an unrestricted educa-
tional grant from CSL Behring. This is the third interna-
tional consensus and is meant to be a living document
requiring continual updating and rethinking. The first
consensus conference was scheduled for Toronto,
Ontario, Canada in April 2003 but was SARSed out.
That conference was rescheduled and held in Toronto
in October 2003 and published in 2004. The next con-
sensus was again held in Toronto Canada in 2006 and
rediscussed in Budapest in 2007 and published in 2008.
This third consensus conference was in danger of being
ashed out from the volcanic activity in Iceland making
planning of such meetings a challenge.
Rare disorders such as Hereditary Angioedema require
international collaboration to push ahead with progress in
the management of the disorders. The Hungarian group
under Dr. Henriette Farkas and the Italian group under
Dr. Marco Cicardi have certainly led the way in organizing
these essential get-togethers. Patient Group participation
in these discussions has been strongly encouraged and the
Consensus Algorithms have been signed off by various
National Patient Organizations. The patients should
decide how they wish to be treated. I usually bore audi-
ences with my motto: It can be done - It must be done for
the sake of our patients. This concept continues in this
third consensus algorithm development. We have moved
from 2003 from only a few controlled trials in prophylaxis
and treatment in HAE-Types I and II to now several clini-
cal trials in various stages of publication. Prophylaxis
options have moved from anti-fibrinolytics and androgens
to include consideration of plasma-derived C1-inhibitor
(pdC1INH) prophylaxis. Therapy options have broadened
from pdC1INH to now include bradykinin receptor
antagonist Icatibant and kallikrein antagonist Ecallantide
and recombinant C1INH under clinical trial. These phase
III clinical trials will move this current consensus algo-
rithm approach to evidence-based approach and Dr.
Marco Cicardi is moving this along with an important
meeting in Italy in September 2010.
Clinical trials in rare disorders are difficult at the best
of times but exceptionally difficult in HAE where swel-
ling events are unpredictable and require quick interven-
tion at all hours of day, night, weekends. These clinical
trials are difficult for patients and clinic staff alike and it
is to the credit of the Patients and the Research Clinics
that these studies have moved along and are either now
published or in stages of publication. However, phase IV
clinical trials and head-to-head evaluation of prophylactic
and therapeutic approaches including cost benefit and
quality of life are still lacking. To date, the clinical trials
have been small and these data may change when larger
trials are undertaken. For example, for many years Beri-
nert (Berinert P in the past and now just called Berinert)
has been used for therapy at doses of one or two vials
(500 to 1000 units; close to 10 units per kg) in thousands
of infusions and appear safe and appear to have success-
fully treated most HAE episodes with second infusions
uncommon. However, when the small clinical phase III
trial was conducted, results showed benefit from 20
units/kg but not 10 units/kg. Since this was the phase III
clinical trial, dose licensing for this drug is 20 units/kg.
This recommendation has great economic impact on the
therapy of this disorder increasing the cost of treatment
by considerable amount. It is essential for national and
international networks of clinics to undertake phase IV
clinical trials to retest this dose-finding. Plasma deriva-
t i v e ss u c ha sp d C 1 I N Ha r ep r e cious resources donated
from dedicated blood donors needing conservation when
possible and such products are costly for individual
patients or treatment programs. The extensive European
clinical experience in hundreds of thousands of infusions
would indicate a lower dose used early in a swelling
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product treatments, these treatments need head-to-head
comparison with the gold standard pdC1INH and each
other so that patients and clinics and payers can make
appropriate cost benefit quality of life based analyses to
strengthen the evidence based recommendations for
management of this disorder.
HAE-Type III has become recognized but whereas the
genetic defect and pathophysiology of Types I and II are
well worked out, the pathophysiology of Type III is still
in its infancy. This group of manuscripts is meant to
discuss the differential diagnosis of hereditary versus
acquired angioedema, help understand the clinical dif-
ferences and approaches to the three types of Hereditary
Angioedema with nuances in females, pregnancy, pedia-
trics, and then adults. These manuscripts are from the
presenters at the 2010 Consensus Conference held in
Toronto Canada and represent some of the background
for discussion for the patient and care teams present as
they discussed the consensus algorithms. The Consensus
Manuscript draft was discussed at the meeting and then
circulated to the other international authors including
patient groups and treatment team leaders. The 2010
International Consensus Algorithm for the Diagnosis,
Therapy and Management of Hereditary Angioedema is
t h er e s u l t .W eh a v ec h o s e nt op u b l i s hi na no nl i n e
open journal to allow wide and timely full free distribu-
t i o no ft h ec o n s e n s u s .W eh o p et h i sg e n e r a t e sf u r t h e r
thoughts and discussions and that Dr. Cicardi will move
the consensus forward to evidence-based approach as
the various trials become published. This is but an algo-
rithm approach in evolution changing as evidence
becomes available. We look forward to the phase IV
clinical phase and much larger clinical trials to further
investigate the most cost effective approach leading to
the best quality of life for all HAE patients.
I would like to congratulate the many Patients who
participate in these very difficult clinical trials and
further congratulate the clinic teams who undertake
these stressful trials requiring 24/7 research team avail-
ability in this unpredictable swelling disorder HAE.
There is much more work to do! Keep up the good
work. I would like to thank the Canadian Society of
Allergy and Clinical Immunology and the University of
Calgary for taking HAE under their wing and supporting
these international consensus meetings.
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